STK39 and Alzheimer disease: Ongoing research is crucial to formulate targeted interventions such as the SPAK inhibitor ZT-1a, capable of modulating astrocyte signaling and mitigating factors contributing to neurodegenerative diseases leading to dementia (VCID and AD).